$TFX

Teleflex Incorporated (TFX) Stock Forecasts

Argus raised its target price for Teleflex Incorporated (TFX) to $133.00. The company, based in Wayne, Pennsylvania, manufactures hospital supplies and medical devices. No other details were provided.

Original reporting
Published Oct 1, 2026, 3:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TFX
Bullish
medium confidence
Mentioned
$TFX
Relevance
7/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$TFXBullishMed
01

Why it matters

The higher target may prompt short-term buying pressure

02

Market read

Analyst target raise is the sole new fact, offering modest trading relevance

03

What to watch

No accompanying earnings or guidance change disclosed

Relevance 7/10Novelty 6/10Timing: today

Background

Brief analyst note raising Teleflex's price target

Company-level read

Ticker impact

$TFXBullishMedium confidence
Context

Analyst raised Teleflex target price to $133.00

Expected impact

potential upward pressure as investors price in higher valuation

Evidence & confidence

New target price is a fresh analyst opinion that may attract buying interest

Market effects

May lift sentiment in the medical device sector

Limited to US healthcare investors

Low

Counterpoint

Target raise could be premature if earnings guidance is weak

Key entities

  • Teleflex Incorporated

    Medical device manufacturer

Related articles

$TFXLow

Teleflex completes enrollment in coronary scaffold study

Teleflex (NYSE:TFX) completed enrollment in its BIOMAG-LL study, evaluating longer Freesolve Resorbable Magnesium Scaffolds for coronary lesions. The trial enrolled 102 patients across Europe, with primary endpoint being Target Lesion Failure rate at 12 months. The study is part of expanding the Freesolve RMS portfolio, according to the company.

$TFXLowAI 8/10

102 patients joined a study of longer artery supports designed to be absorbed

Teleflex Inc. completed enrollment of 102 patients in the BIOMAG™-LL Clinical Study across 14 European centers to evaluate 35 mm and 40 mm Freesolve™ Resorbable Magnesium Scaffolds for long coronary lesions. The study aims to assess safety and effectiveness, with primary endpoint Target Lesion Failure (TLF) rate at 12 months. The data could expand treatment options for diffuse coronary artery disease, supporting the broader use of resorbable scaffold technology.

$TFXHigh

Why Teleflex (TFX) Stock Is Trading Up Today

Teleflex (TFX) stock rose 4.5% after BofA Securities upgraded it to Buy and raised its price target to $158 from $145. The shares closed at $127.39, up 4.4%. The company's shares have been volatile, with significant moves over the past year, including a 15.5% drop after a weak earnings report. TFX is up 4.1% year-to-date but remains 10.3% below its 52-week high.

$TFXHigh

Why is Teleflex stock rallying today?

Teleflex (TFX) stock rose 4.6% after BofA upgraded it to Buy, raising its price target to $158. The bank cited improved execution risks and potential EPS upside. Zacks Research also upgraded the stock to Strong-Buy. The company's recent earnings beat expectations. The S&P 500, Dow Jones, and Nasdaq all declined, highlighting the company-specific nature of the rally.

$IARTMedAI 8/10

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.